Myrcludex B/Bulevirtide peptide
Not For Human Use, Lab Use Only.
Cat.#: 319769
Special Price 459.00 USD
Availability:
5 weeks
-
Product Name
Myrcludex B/Bulevirtide peptide
-
Documents
Batch to batch variation of the purity
-
Sequence Shortening
Myr-GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANKVG-NH2
-
Sequence
Myr-Gly-Thr-Asn-Leu-Ser-Val-Pro-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His-Gln-Leu-Asp-Pro-Ala-Phe-Gly-Ala-Asn-Ser-Asn-Asn-Pro-Asp-Trp-Asp-Phe-Asn-Pro-Asn-Lys-Asp-His-Trp-Pro-Glu-Ala-Asn-Lys-Val-Gly-NH2
-
Length (aa)
47
-
Peptide Purity (HPLC)
95.51%
-
Molecular Formula
C248H355N65O72
-
Molecular Weight
5398.84
-
CAS No.
2012558-47-1
-
PubChem CID
134687648
-
Source
Synthetic
-
Form
Powder
-
Description
Myrcludex B, also known as Bulevirtide, is a synthetic lipopeptide derived from the preS1 domain of the hepatitis B virus (HBV) envelope protein. This peptide specifically targets hepatocytes and efficiently blocks HBV entry by interfering with the viral receptor binding process. Myrcludex B has been demonstrated to prevent both de novo infection and intrahepatic viral spreading in experimental models, highlighting its potential as a potent HBV entry inhibitor.
The mechanism of action involves the inhibition of HBV dissemination among hepatocytes, effectively limiting the amplification of covalently closed circular DNA (cccDNA) within infected cells. Studies have shown that Myrcludex B maintains its inhibitory effect without altering virion productivity or hepatocyte viability, making it a selective and reversible blocker of HBV infection. Its ability to hinder viral spreading underscores its significance in studying HBV-host interactions and viral entry mechanisms.
-
Storage Guidelines
Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides
-
References
- Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013 May;58(5):861-7. doi: 10.1016/j.jhep.2012.12.008. Epub 2012 Dec 13. PMID: 23246506.
-
About TFA salt
Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.
Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.
Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.
In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.
-
Molar Concentration Calculator
-
Dilution Calculator
-
Percent Concentration Calculator
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Related Products / Services
• Peptide Services: NovoPro's peptide synthesis services include standard chemical peptide synthesis, peptide modification, peptide libraries, and recombinant peptide expression.
• Standard Peptide Synthesis: NovoPro offers quality peptides at the most competitive prices in the industry, starting at $3.20 per amino acid. NovoPro provides PepBox – Automatic Quote Tool for online price calculation.
• Peptide Modifications: NovoPro offers a wide range of peptide modification services including isotope labeling (2H, 15N, and 13C), multiple disulfide bonds, multiple phosphorylations, KLH, BSA, ovalbumin, amidation, acetylation, biotin, FITC, etc.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"